UPDATE: Morgan Stanley Reiterates On Amgen, Inc. As Brodalumab Doesn't Need To Be Forgotten - Amgen (NASDAQ:AMGN)

Crypto Whales Are Loading Up — Are You?

New research shows the biggest crypto buyers are back. And this time? They could hold for the possibility that Bitcoin will surpass $100,000 in 2024. You don’t want to miss the next massive crypto bull run like we saw in 2020 and 2021. To know exactly what’s going on and what to buy… Get Access To Benzinga’s Best Crypto Research and Investments For Only $1.

In a report published Wednesday, Morgan Stanley analyst Matthew Harrison reiterated an Overweight rating on

Crypto Whales Are Loading Up — Are You?

ENTER TO WIN $500 IN STOCK OR CRYPTO

Enter your email and you'll also get Benzinga's ultimate morning update AND a free $30 gift card and more!

Amgen, Inc.

(NASDAQ: AMGN), but removed the $143.00 price target.In the report, Morgan Stanley noted, “Amgen is developing brodalumab together with AstraZeneca. We currently model Amgen recording total sales and paying AstraZeneca out of COGS. The 1st of three PhIII studies has been reported (see our 5/12/14 note). The remaining two head-to-head studies versus J&J's Stelara (AMAGINE-2 & -3) are expected in 4Q14. We expect global filings in 1H15. Key competitors are Novartis (secukinumab) and Lilly (ixekizumab).”Amgen closed on Tuesday at $139.33.